Phase I trial, Quotient Sciences code: QSC206403 [The full scientific title will be published within 30 months after the end of the trial]
ANAVEX2-73-RS-003 is a Phase 2/3, Double-blind, Randomized, Placebo-controlled Safety and Efficacy Study in Pediatric Patients With RTT
ANAVEX2-73-RS-003 is a Phase 2/3, double-blind, randomized, placebo-controlled dose escalation safety, tolerability and efficacy study in patients 5-17 years of age with RTT using endpoints including multiple clinical and exploratory molecular and biochemical measures.
Open Label Extension Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001
This is a Phase 2 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and efficacy of daily treatment.
100 Clinical Results associated with Anavex Germany GmbH
0 Patents (Medical) associated with Anavex Germany GmbH
100 Deals associated with Anavex Germany GmbH
100 Translational Medicine associated with Anavex Germany GmbH